Thus, as already underlined in previous sections, inhibition of CGRP through anti-CGRP mAbs, used for migraine prevention, would have the potential of being beneficial in visceral pain conditions where sensitization is documented, e.g., irritable bowel syndrome or PBS, only to mention some, therefore impacting two pain conditions (migraine and visceral pain) at the same time. The gene discussed is CALCA; the disease is migraine disorder.